ClinicalTrials.gg
RecruitingNCT05685433RECIPEUpdated Oct 19, 2026

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

An interventional study of eCoin Tibial Nerve Stimulation in Overactive Bladder, Urge Incontinence and Incontinence, Urinary, sponsored by Valencia Technologies Corporation. Recruiting at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Updated Oct 19, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.

Planned enrollment
75th of 288
200 · median 66
Started
2023
with 20 others
No phase
113 of 333
20 open now
Primary completion
2028-04
later than 41 of 47 live
Registered
277th of 333
by date

Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 75th largest by planned enrollment of the 288 interventional ones that give a count, is one of 21 that started in 2023, is one of 113 with no phase, reaches primary completion later than 41 of the 47 other live ones, and was the 277th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Urinary Bladder, Overactive with a site in United States, or all of them as a file.
02

Study summary

A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).

Read the detailed description

The goal of this prospective, multicenter, single-arm study is to assess the long-term safety and effectiveness of the FDA approved eCoin® implanted tibial nerve stimulator in a real world setting. Eligible subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI) will be implanted with the eCoin® implanted tibial stimulator and complete voiding diaries and questionnaires at follow-up visits through 5 years.

03

Conditions studied

  • Overactive Bladder
  • Urge Incontinence
  • Incontinence, Urinary
  • Urinary Urge Incontinence
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population
  • Individual with diagnosis of overactive bladder with urgency urinary incontinence.
  • Individual has at least one urgency urinary incontinence episode on each of three days as determined on a 3-day voiding diary.
  • Individual gives written .
  • Individual is mentally competent and able to understand all study requirements.
  • Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.
  • Individual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to starting the baseline diary, or longer if the physician judges that the therapeutic effect is still present.
  • Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).
  • Individual is determined to be a suitable surgical candidate by physician.
  • Individual is appropriate for eCoin treatment based on the US FDA-approved IFU requirements.

Exclusion criteria

Exclusion Criteria:

  • Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.
  • Individual has bladder outlet obstruction. (Suspected bladder outlet obstruction will be initially assessed by uroflow study with those having a maximum flow rate \< 15mL/s requiring additional evaluation.)
  • Individual has predominantly stress urinary incontinence (greater than 1/3 of leaks on baseline diary are stress).
  • Individual has an active urinary tract infection at time of enrollment.
  • Individual has known polyuria.
  • Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome.
  • Individual has abnormal post void residual (i.e. greater than 200 cc initially and on repeat testing after double voiding)
  • Individual has clinically significant urethral stricture disease or bladder neck contracture. (Suspected disease or contracture will be initially assessed by uroflow study with those having a maximum flow rate \< 15mL/s requiring additional evaluation.)
  • Individual has chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region.
  • Individual has morbid obesity and in the opinion of the investigator is not a good candidate for the study.
  • Individual has had diagnosis of bladder, urethral, or prostate cancer.
  • Individual has had a prior anti-stress incontinence sling surgery within the last year.
  • Individual is pregnant or intends to become pregnant during the study.
  • Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.
  • Individual has uncontrolled diabetes mellitus (>7) or diabetes with significant peripheral complications. (Uncontrolled diabetes will be ruled out by blood test excluding those with Hemoglobin A1C>7).
  • Individual has an implantable neurostimulator, pacemaker, or implantable cardiac defibrillator (ICD).
  • Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment, or more time if the principal investigator judges that the therapeutic effect is present.
  • Individual has been treated with percutaneous tibial nerve stimulation (PTNS) within the previous 4 weeks prior to enrollment or more time if the principal investigator judges that the therapeutic effect is present.
  • Individual is currently using transcutaneous electrical nerve stimulation (TENS) in the pelvic region, back, or legs.
  • Individual is aware that he or she will need an MRI scan other than a head/neck/shoulder MRI during the study period.
  • Individual has a clotting or bleeding disorder or is using anticoagulant therapies and in the opinion of the investigator is not a good candidate for the study (antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator).
  • Individual is neutropenic or immune-compromised.
  • Individual has had previous surgery and/or significant scarring at the implant location.
  • Individual has ongoing dermatologic condition at the implant site, including but not limited to dermatitis and disorders.
  • Individual has a clinically significant peripheral neuropathy in the lower extremities.
  • Individual has neurogenic bladder dysfunction.
  • Individual has pitting edema at implant location (≥ 2+ is excluded).
  • Individual has inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.
  • Individual has varicose veins and is symptomatic.
  • Individual has open wounds or trauma in the lower extremities.
  • Individual has arterial disease in the lower extremities.
  • Individual has vasculitis in the lower extremities.
  • Individual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 RBC's /HPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)
  • In the opinion of the investigator, Individual is not a good candidate for participation in the study.

Please Note: "lower extremities" refers to lower leg and foot.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    eCoin Tibial Nerve Stimulation

    Subcutaneous stimulation of the tibial nerve using the eCoin device.

    Device: eCoin Tibial Nerve Stimulation

Interventions

  • DeviceeCoin Tibial Nerve Stimulation

    Subcutaneous stimulation of the tibial nerve using the eCoin device.

06

What researchers measure

Primary outcomes

  1. Responder Rate

    Proportion of subjects achieving at least a 50% improvement in the number of urgency urinary incontinence episodes on a 3-day voiding diary.

    Time frame: 12 months

  2. Safety: 12 months rate of all device or procedure related AEs.

    Rate of all device or procedure related AEs.

    Time frame: 12 months

Secondary outcomes

  1. Responder Rate

    Proportion of subjects achieving at least a 50% improvement in the number of urgency urinary incontinence episodes on a 3-day voiding diary.

    Time frame: 24 months

  2. Safety Data

    Rate of all device or procedure related AEs through 24 months post activation of eCoin.

    Time frame: 24 months

  3. Safety data through 7 months post-reimplantation.

    Rate of device or procedure-related AEs through 7 months post reimplantation.

    Time frame: 7 months post reimplantation

Other outcomes

  1. Proportion of responders (50% improvement) after 12, 24, 36, 48, and 60 months of therapy.

    Proportion of subjects achieving at least a 50% improvement in the number of urgency urinary incontinence episodes on a 3-day voiding diary.

    Time frame: 12, 24, 36, 48, and 60 months

  2. Proportion of responders (75% improvement) after 12, 24, 36, 48, and 60 months of therapy.

    Proportion of subjects achieving at least a 75% improvement in the number of urgency urinary incontinence episodes on a 3-day voiding diary.

    Time frame: 12, 24, 36, 48, and 60 months

  3. Proportion of responders (100% improvement) after 12, 24, 36, 48, and 60 months of therapy.

    Proportion of subjects achieving at least a 100% improvement in the number of urgency urinary incontinence episodes on a 3-day voiding diary.

    Time frame: 12, 24, 36, 48, and 60 months

  4. Reduction in the number of urgency urinary incontinence episodes.

    Reduction in the number of urgency urinary incontinence episodes on a 3-day voiding diary.

    Time frame: 12, 24, 36, 48, and 60 months

  5. Reduction in the number of urgency urinary incontinence episodes for subjects with 8+ voids per day at baseline.

    Reduction in the number of urgency urinary incontinence episodes on a 3-day voiding diary for subjects who experience more than 8 voids per day at baseline.

    Time frame: 12, 24, 36, 48, and 60 months

  6. Reduction in urgency episodes.

    Reduction in the number of urgency episodes on a 3-day voiding diary.

    Time frame: 12, 24, 36, 48, and 60 months

  7. Reduction in nocturia episodes

    Reduction in nocturia episodes on a 3-day voiding diary.

    Time frame: 12, 24, 36, 48, and 60 months

  8. Patient reported qualify of life

    Improvement in patient reported qualify of life utilizing the Overactive Bladder Symptom Quality of Life Questionnaire (OABq).

    Time frame: 12, 24, 36, 48, and 60 months

  9. Patient reported overactive bladder condition improvement.

    Improvement in patient reported overactive bladder condition utilizing the Patient Global Impression of Improvement (PGI-I) questionnaire.

    Time frame: 12, 24, 36, 48, and 60 months

  10. Patient reported sexual health.

    Assess patient reported sexual health using the PROMIS Sexual Function and Satisfaction survey.

    Time frame: 12 months

  11. Patient reported satisfaction with eCoin.

    Assess patient-reported satisfaction with eCoin therapy using the custom patient satisfaction rating survey.

    Time frame: 12, 24, 36, 48, and 60 months

  12. Device-related adverse events from implantation.

    Rate of device-related adverse events from implantation.

    Time frame: 12, 24, 36, 48, and 60 months

  13. Procedure-related adverse events from implantation.

    Rate of procedure-related adverse events from implantation.

    Time frame: 12, 24, 36, 48, and 60 months

  14. Procedure-related adverse events due to suture technique

    Rate of procedure-related adverse events occurring as a result of inappropriate suture technique.

    Time frame: 12, 24, 36, 48, and 60 months

07

Study locations

19 of 22 sites recruiting
  • Urology Centers of Alabama
    Homewood, Alabama 35209, United States
    Recruiting
    • Alison Pickering, MD · Contact
  • USA Health
    Mobile, Alabama 36606, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Arkansas Urology
    Little Rock, Arkansas 72211, United States
    Recruiting
    • Lauren Hendrix, MD · Contact
    • Lauren Hendrix, MD · Principal investigator
  • University of California, Irvine
    Irvine, California 92697, United States
    Recruiting
    • Dena Moskowitz, MD · Contact
    • Dena Moskowitz, MD · Principal investigator
  • AIR Research
    Los Angeles, California 90017, United States
    Recruiting
    • John Kowalczyk, DO · Contact
    • John Kowalczyk, DO · Principal investigator
  • Stanford Health
    Stanford, California 94305, United States
    Recruiting
    • Craig Comiter, MD · Contact
    • Craig Comiter, MD · Principal investigator
  • Urological Research Network Corp
    Hialeah, Florida 33016, United States
    Recruiting
    • Isabel H Lopez, MBA · Contactisabel@besturology.net · 786-431-2014
    • Edward Gheiler, MD · Principal investigator
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
    Recruiting
  • Rush University
    Chicago, Illinois 60612, United States
    Recruiting
    • Sarah Adelstein, MD · Contact
    • Sarah Adelstein, MD · Principal investigator
  • The Iowa Clinic
    Ankeny, Iowa 50023, United States
    Recruiting
    • Stephanie Morgan, MD · Contactspmorgan@iowaclinic.com · 515-875-9815
    • Stephanie Morgan, MD · Principal investigator
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • Annah Vollstedt, MD · Contact
    • Annah Vollstedt, MD · Principal investigator
  • University of Kansas Medical Center Research Institute, Inc
    Kansas City, Kansas 66160, United States
    Recruiting
    • Kirk Redger, MD · Contact
    • Kirk Redger, MD · Principal investigator
  • Cypress Medical Research
    Wichita, Kansas 67226, United States
    Recruiting
    • Kevin Miller, MD · Contact
    • Kevin Miller, MD · Principal investigator
  • Louisiana State University Health Sciences Center
    Shreveport, Louisiana 71103, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Minnesota Urology
    Woodbury, Minnesota 55125, United States
    Recruiting
    • Michael Ehlert, MD · Contact
    • Michael Ehlert, MD · Principal investigator
  • Specialty Clinical Research of St. Louis
    St Louis, Missouri 63141, United States
    Recruiting
    • Travis Bullock, MD · Contact
    • Travis Bullock, MD · Principal investigator
  • Weill Cornell Medicine: Department of Urology
    New York, New York 10065, United States
    Recruiting
    • Larissa Rodriguez, MD · Contact
    • Larissa Rodriguez, MD · Principal investigator
  • The Oregon Clinic
    Portland, Oregon 97225, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Southern Urogynecology
    West Columbia, South Carolina 29169, United States
    Recruiting
    • Andrea Pezzella, MD · Contact
    • Andrea Pezzella, MD · Principal investigator
  • UPNT Research Institute
    Arlington, Texas 76017, United States
    Recruiting
    • Tracy Cannon-Smith, MD · Contact
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
    • Christopher Smith, MD · Contact
    • Christopher Smith, MD · Principal investigator
  • The Methodist Hospital Research Institute
    Houston, Texas 77030, United States
    Recruiting
    • Kathleen Kobashi, MD · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Apr 2028, 63 months after the start.

Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's planned 63 months is above that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Mar 2027 → Apr 2028 and completion Dec 2031 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2023
First posted
Jan 17, 2023
StartActual
Jan 26, 2023
Primary completionEst.
Apr 2028was Mar 2027
CompletionEst.
Dec 2032was Dec 2031
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Apr 2028
Oct 19, 2026
Study completion
Dec 2031→Dec 2032
Oct 19, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedIndividual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to starting the baseline diary, or longer if the physician judges that the therapeutic effect is still present.
Exclusion criteria
  • EditedIndividual has open wounds, trauma, or prior surgerytrauma in the lower extremities.
  • EditedIndividual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 PBCRBC's /HPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)
  • AddedPlease Note: "lower extremities" refers to lower leg and foot.
Oct 19, 2026
Contact
Study contact's phone or email changed: •••7775→•••2469; d•••@valenciatechnologies.com→d•••@bsci.com. See the current contact
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Mar 2027→Apr 2028
    Study completion Dec 2031→Dec 2032
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedIndividual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to starting the baseline diary, or longer if the physician judges that the therapeutic effect is still present.
    Exclusion criteria
    • EditedIndividual has open wounds, trauma, or prior surgerytrauma in the lower extremities.
    • EditedIndividual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 PBCRBC's /HPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)
    • AddedPlease Note: "lower extremities" refers to lower leg and foot.
    Contact Study contact's phone or email changed: •••7775→•••2469; d•••@valenciatechnologies.com→d•••@bsci.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05685433
Lead sponsor
Valencia Technologies Corporation
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Jan 26, 2023
Primary completion
Apr 2028 (estimated)
Completion
Dec 2032 (estimated)
Last update
Oct 19, 2026

Study contacts

Dylan Beyer
Contact
dylan.beyer@bsci.com
385-456-2469

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion